Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia

Jung, Kyong Yeun; Kim, Kyoung Min; Han, Sun Kyoung; Han, Yugui; Oh, Tae Jung; Choi, Sung Hee; Park, Kyong Soo; Jang, Hak Chul; Lim, Soo

doi:10.1253/circj.cj-17-0411

Cited by 8 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, the baseline CEC predicts the incidence of MACE, in particular, of coronary revascularization, in patients with CAD, including the boarder baseline CEC level of 1. Several interventions recommended as the optimal secondary preventions of CAD have been described and function to improve CEC level up to 1; these include pharmacological interventions by rosuvastatin 12) , ezetimibe 13) , eicosapentaenoic acid 14) , and intensive cardiac rehabilitation, including smoking cessation 15) and improvement of diabetes state 9) .…”

Section: Advance Publication Journal Of Atherosclerosis and Thrombosismentioning

confidence: 99%

High-Density Lipoprotein Cholesterol Efflux Capacity as a Novel Prognostic Surrogate for Coronary Artery Disease

Hisauchi

Ishikawa

Ayaori

et al. 2021

JAT

View full text Add to dashboard Cite

We examined the impact of baseline high-density lipoprotein cholesterol efflux capacity (CEC) on major cardiac adverse events (MACE) in patients with coronary artery disease (CAD) during a long-term secondary prevention. Method: CEC was measured using a cell-based efflux system in (3)[H]-cholesterol-labeled J774 macrophages in apolipoprotein B-depleted plasma between January 2011 and January 2013. Patients with CAD were divided into 2 groups as a boundary CEC value of 1: 0.19 ≤ CEC 1 (impaired CEC group, mean CEC of 0.76 0.16, n 136), and 1 ≤ CEC ≤ 2.08 (enhanced CEC group, 1.20 0.19, n 44). MACE, comprised the incidence of cardiac death, non-fatal myocardial infarction, and any revascularizations (RV) without restenosis approximately 1 year after vascularization, was retrospectively investigated at September 2019. Impact of enhanced CEC on MACE among 22 variables was examined by applying a Cox proportional hazard model. Result:The frequency of MACE in impaired CEC group (16.9%, mean observational interval of 2111 888 days) was significantly higher than that in enhanced CEC group (2.3%, 2,252 685, p 0.013), largely driven by the significantly higher RV incidence (14.0 % versus 2.3 %, p 0.032). Enhancement of CEC was the significant predictor of MACE (hazard ratio: 0.11; 95% CI: 0.013-0.879; p 0.038). Conclusion:A baseline CEC level of more than 1 in patients with CAD brought favorable long-term clinical outcomes, suggesting that CEC is a useful prognostic and therapeutic surrogate for secondary prevention of CAD.apy of LDL-C 1) . Among the pleiotropic atheroprotective effects of high-density lipoprotein cholesterol (HDL-C), cholesterol efflux from macrophage (cholesterol efflux capacity, CEC) was consistently demonstrated as a negative predictor of CAD, independent of HDL-C and LDL-C levels 2, 3) . In addition, the CEC in asymptomatic healthy subjects predicts the incidence of atherosclerotic cardiovascular events

show abstract

Section: Advance Publication Journal Of Atherosclerosis and Thrombosismentioning

confidence: 99%

High-Density Lipoprotein Cholesterol Efflux Capacity as a Novel Prognostic Surrogate for Coronary Artery Disease

Hisauchi

Ishikawa

Ayaori

et al. 2021

JAT

View full text Add to dashboard Cite

show abstract

“…10, 11 In this issue of the Journal, Jung et al report that in diabetic patients with dyslipidemia rosuvastatin 20 mg treatment increased HDL function as assessed by CE capacity, improved vascular endothelial function (flowmediated dilatation (FMD) of the brachial artery), reduced carotid intima-media thickness (cIMT), and favorably changed biomarkers related to lipid metabolism and atherosclerosis. 12 Favorable effects of intensive statin treatment on HDL function to ameliorate CE capacity in addition to lipid-related biomarkers have already been acknowledged, 13 even in diabetic patients. 14 Thus, the novel findings of the study by Jung et al are largely confined to the relationship between increased CE capacity and changes in FMD and cIMT.…”

Section: Editorial Advance Publication By-j-stagementioning

confidence: 99%

Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease?

Sakuma

Ikewaki

2018

Circ J

View full text Add to dashboard Cite

Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study

Seo

Kim

et al. 2020

Heart Vessels

View full text Add to dashboard Cite

Effect of Rosuvastatin on Cholesterol Efflux Capacity and Endothelial Function in Type 2 Diabetes Mellitus and Dyslipidemia

Cited by 8 publications

References 51 publications

High-Density Lipoprotein Cholesterol Efflux Capacity as a Novel Prognostic Surrogate for Coronary Artery Disease

High-Density Lipoprotein Cholesterol Efflux Capacity as a Novel Prognostic Surrogate for Coronary Artery Disease

Should Measures of High-Density Lipoprotein Function Be Added to the Low-Density Lipoprotein Cholesterol Target Level-Based Guidelines for Prevention of Atherosclerotic Disease?

Clinical impact of statin therapy on vasospastic angina: data from a Korea nation-wide cohort study

Contact Info

Product

Resources

About